These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25897220)

  • 1. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
    Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
    Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.
    Ding P; Jin Q; Chen X; Yang S; Guo J; Xing G; Deng R; Wang A; Zhang G
    Int J Nanomedicine; 2019; 14():7533-7548. PubMed ID: 31571862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
    Bernasconi V; Bernocchi B; Ye L; Lê MQ; Omokanye A; Carpentier R; Schön K; Saelens X; Staeheli P; Betbeder D; Lycke N
    Front Immunol; 2018; 9():2060. PubMed ID: 30271406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.
    Deng L; Ibañez LI; Van den Bossche V; Roose K; Youssef SA; de Bruin A; Fiers W; Saelens X
    PLoS One; 2015; 10(5):e0126650. PubMed ID: 25973787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.
    Wang Y; Deng L; Gonzalez GX; Luthra L; Dong C; Ma Y; Zou J; Kang SM; Wang BZ
    Adv Healthc Mater; 2020 Jan; 9(2):e1901176. PubMed ID: 31840437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
    Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
    Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.
    Deng L; Kim JR; Chang TZ; Zhang H; Mohan T; Champion JA; Wang BZ
    Virology; 2017 Sep; 509():82-89. PubMed ID: 28622575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
    Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
    Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.